ELIS·ELIS

ELIS is currently experiencing positive momentum, primarily driven by developments at LLY. The recent announcement of positive Phase 3 results for Retevmo in lung cancer, alongside strong GLP-1 demand, is bolstering LLY's outlook. This positive sentiment is reinforced by LLY's proactive measures to build a substantial pre-launch inventory of orforglipron, its oral weight loss drug, to meet anticipated demand. Increased institutional investment, including a significant stake increase by JPMorgan, reflects growing confidence in LLY's growth trajectory. However, Liberty One's reduction in its position in Lamb Weston, a top holding for the firm, introduces a note of caution. LLY is also expanding beyond GLP-1 with RNA-based cancer therapies and AI-driven drug development. Traders should monitor LLY's presentation at the TD Cowen Health Care Conference on March 2, 2026, for further insights into its evolving strategy and potential impact on the ETF.